Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrate.
Plasma was obtained from two patients with severe factor IX deficiency who had developed specific inhibitors of factor IX. Immunochemical characterization of the inhibitors by coagulation inhibitor neutralization assays and by immunoelectrophoretic methods demonstrated that both were IgG antibodies. One of the antibodies appeared to be monoclonal in origin with IgG subclass 4 heavy chains and lambda light chains. The other appeared to be oligoclonal and contained IgG subclass 1 and subclass 4 heavy chains and kappa and lambda light chains. One of the patients was treated with conventional, non-activated factor IX concentrate and with activated factor IX concentrate (Feiba) for repeated bleeding episodes. Administration of Feiba resulted in a progressive shortening of the kaolin cephalin clotting time and was followed by a good clinical response. Infusion of non-activated factor IX concentrate failed to induce clinical resolution of haemarthroses and had minimal effect on laboratory tests. The presence of circulating immune complexes could not be demonstrated in this patient.
D000328:Adult; D002648:Child; D005164:Factor IX / Q000008:administration & dosage* / Q000276:immunology*; D015949:Factor IXa; D002836:Hemophilia B / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007123:Immunoelectrophoresis, Two-Dimensional; D007518:Isoantibodies / Q000032:analysis*; D008297:Male; D009500:Neutralization Tests; D010314:Partial Thromboplastin Time; D014914:Whole Blood Coagulation Time
D007518:Isoantibodies; D005164:Factor IX; D015949:Factor IXa